Laura San-Segundo
Overview
Explore the profile of Laura San-Segundo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diaz-Tejedor A, Rodriguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, Gonzalez-Rodriguez M, Castellanos B, et al.
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38731936
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of...
2.
Alvarez-Vazquez A, San-Segundo L, Cervero-Garcia P, Flores-Hernandez R, Ollauri-Ibanez C, Segura-Collar B, et al.
Neuro Oncol
. 2024 Mar;
26(7):1230-1246.
PMID: 38507464
Background: Glioblastoma (GBM) commonly displays epidermal growth factor receptor (EGFR) alterations (mainly amplification and EGFRvIII) and TAT-Cx43266-283 is a Src-inhibitory peptide with antitumor properties in preclinical GBM models. Given the...
3.
Ovejero-Sanchez M, Rubio-Heras J, Vicente de la Pena M, San-Segundo L, Perez-Losada J, Gonzalez-Sarmiento R, et al.
Int J Mol Sci
. 2022 Jul;
23(14).
PMID: 35886866
Ovarian cancer (OC) is the most lethal gynecological malignancy; therefore, more effective treatments are urgently needed. We recently reported that chloroquine (CQ) increased reactive oxygen species (ROS) in OC cell...
4.
Algarin E, Quwaider D, Campos-Laborie F, Diaz-Tejedor A, Mogollon P, Vuelta E, et al.
Cells
. 2021 Apr;
10(3).
PMID: 33806619
BH3-mimetics targeting anti-apoptotic proteins such as MCL-1 (S63845) or BCL-2 (venetoclax) are currently being evaluated as effective therapies for the treatment of multiple myeloma (MM). Interleukin 6, produced by mesenchymal...
5.
Garcia-Gomez A, Li T, de la Calle-Fabregat C, Rodriguez-Ubreva J, Ciudad L, Catala-Moll F, et al.
Nat Commun
. 2021 Jan;
12(1):421.
PMID: 33462210
Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing...
6.
Paino T, Gonzalez-Mendez L, San-Segundo L, Corchete L, Hernandez-Garcia S, Diaz-Tejedor A, et al.
Cancers (Basel)
. 2020 Sep;
12(10).
PMID: 32987735
Background: Proviral Insertion site for Moloney murine leukemia virus (PIM) kinases are overexpressed in hematologic malignancies, including multiple myeloma. Previous preclinical data from our group demonstrated the anti-myeloma effect of...
7.
Algarin E, Diaz-Tejedor A, Mogollon P, Hernandez-Garcia S, Corchete L, San-Segundo L, et al.
Haematologica
. 2019 Jul;
105(3):e116-e120.
PMID: 31320555
No abstract available.
8.
Martin-Granado V, Ortiz-Rivero S, Carmona R, Gutierrez-Herrero S, Barrera M, San-Segundo L, et al.
Oncotarget
. 2018 Jan;
8(67):110994-111011.
PMID: 29340032
Previous observations indicated that C3G (RAPGEF1) promotes α-granule release, evidenced by the increase in P-selectin exposure on the platelet surface following its activation. The goal of the present study is...
9.
Hernandez-Garcia S, San-Segundo L, Gonzalez-Mendez L, Corchete L, Misiewicz-Krzeminska I, Martin-Sanchez M, et al.
Haematologica
. 2017 Sep;
102(12):2113-2124.
PMID: 28860344
Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma...
10.
Rojas E, Corchete L, San-Segundo L, Martinez-Blanch J, Codoner F, Paino T, et al.
Clin Cancer Res
. 2017 Aug;
23(21):6602-6615.
PMID: 28790111
The search for new drugs that control the continuous relapses of multiple myeloma is still required. Here, we report for the first time the potent antimyeloma activity of amiloride, an...